Boston Scientific (BSX) Receives a Buy from Argus Research
Argus Research analyst David Toung maintained a Buy rating on Boston Scientific (BSX – Research Report) on February 14. The company’s shares ...
Boston Scientific price target raised to $130 from $105 at Argus
Argus raised the firm’s price target on Boston Scientific (BSX) to $130 from $105 and keeps a Buy rating on the shares. The firm sees strong ...
Medindia19h
Benign Prostatic Hyperplasia Surgical Treatment Market to Hit USD 17.19 Billion by 2030 with 5.3% CAGR | MarketsandMarkets™
The global Benign Prostatic Hyperplasia Surgical Treatment market, valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR of 5.3%, reaching US$12.62 billion in 2024 and an ...